The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
Author Information
Author(s): Yu Liang-He, Li Nan, Cheng Shu-Qun
Primary Institution: Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China
Hypothesis
Can preoperative antiviral therapy improve liver function and reduce recurrence of HBV-related hepatocellular carcinoma?
Conclusion
Antiviral therapy may improve liver function and reduce the risk of recurrence in patients with HBV-related hepatocellular carcinoma.
Supporting Evidence
- High serum HBV DNA levels are a strong predictor of HCC independent of other factors.
- Antiviral therapy may lower the risk of HCC recurrence after surgery.
- Patients treated with antiviral therapy had better liver function post-surgery.
Takeaway
This study looks at how treating hepatitis B with antiviral drugs can help people with liver cancer live longer and have fewer problems after surgery.
Methodology
Review of existing studies on the impact of antiviral therapy on HBV-related hepatocellular carcinoma.
Potential Biases
Potential publication bias in the studies reviewed.
Limitations
The study relies on existing literature, which may have varying methodologies and sample sizes.
Participant Demographics
Patients with chronic hepatitis B and hepatocellular carcinoma, primarily from China, Taiwan, and Senegal.
Statistical Information
P-Value
0.0384
Confidence Interval
95% CI 3.3–151
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website